Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | EBP | Q15125 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7237714 | 0.88 | CYP3A4 (0.46) | CYP3A4USP2MAPK1SMN1; SMN2GSK3B | |
| SCHEMBL12248740 | 0.85 | HPGDS (0.47) | CYP3A4SMN1; SMN2GSK3BALDH1A1HPGDS | |
| SCHEMBL8546247 | 0.82 | CYP3A4 (0.55) | CYP3A4USP2MAPK1SMN1; SMN2CYP2D6 | |
| SCHEMBL827858 | 0.81 | CYP3A4 (0.53) | CYP3A4USP2MAPK1SMN1; SMN2CYP2D6 | |
| SCHEMBL2381417 | 0.81 | GSK3B (0.52) | CYP3A4MAPK1GSK3BALDH1A1KMT2A | |
| SCHEMBL733130 | 0.80 | MAPT (0.46) | CYP3A4SMN1; SMN2GSK3BCYP2D6LMNA | |
| SCHEMBL1612678 | 0.80 | HPGDS (0.44) | CYP3A4USP2MAPK1SMN1; SMN2GSK3B | |
| SCHEMBL4727216 | 0.79 | CYP2D6 (0.57) | CYP3A4USP2MAPK1SMN1; SMN2CYP2D6 | |
| SCHEMBL22498722 | 0.79 | CYP3A4 (0.56) | CYP3A4USP2MAPK1SMN1; SMN2CYP2D6 | |
| SCHEMBL7193907 | 0.79 | CYP2D6 (0.57) | CYP3A4USP2MAPK1SMN1; SMN2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896401-B1 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | UNIV TEMPLE (US) | 2013-04-10 | — | — | EP | claimed |
| US-8143453-B2 | Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis | Temple University—Of the Commonwealth System of Higher Education (US) | 2012-03-27 | — | — | US | claimed |
| US-20090124828-A1 | Unsaturated Sulfides, Sulfones, Sulfoxides and Sulfonamides Synthesis | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-05-14 | — | — | US | claimed |
| EP-1896401-A2 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | Temple University of the Commonwealth System of Higher Education (US) | 2008-03-12 | — | — | EP | claimed |
| WO-2006091870-A2 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-08-31 | — | — | WO | claimed |
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION | 2021-07-27 | — | — | US | disclosed |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2020-03-17 | — | — | US | disclosed |
| EP-2785714-B1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2018-11-21 | — | — | EP | disclosed |
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | DEVELOPMENT CENTER OF BIOTECHNOLOGY (TW) | 2018-11-08 | — | — | US | disclosed |
| US-9409902-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2016-08-09 | — | — | US | disclosed |
| US-9409902-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2016-08-09 | — | — | US | disclosed |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2015-09-10 | — | — | US | disclosed |
| US-20090124828-A1 | Unsaturated Sulfides, Sulfones, Sulfoxides and Sulfonamides Synthesis | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1896401-A2 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | Temple University of the Commonwealth System of Higher Education (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006091870-A2 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-08-31 | — | — | WO | disclosed |
| US-RE37094-E1 | Heterocyclic substituted acylaminothiazoles, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2001-03-13 | — | — | US | disclosed |
| EP-0564924-B1 | 2-Oxoethyl derivatives as immunosuppressants | BAYER AG (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5686424-A | FOR TREATING INFLAMMATION | MILES INC. (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0564924-A2 | 2-Oxoethyl derivatives as immunosuppressants | Bayer Corporation (US) | 1993-10-13 | — | — | EP | disclosed |
| US-5189049-A | Cholecystokinin and gastrin inhibitors | SANOFI (FR) | 1993-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | CYP3A4 3983/4885USP2 1461/4885MAPK1 1556/4885 |
| US-20090124828-A1 | Unsaturated Sulfides, Sulfones, Sulfoxides and Sulfonamides Synthesis | SULT2A1, SULT1A1, ARSA | CYP3A4 1638/4885USP2 821/4885MAPK1 1863/4885 |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | CYP3A4 3983/4885USP2 1461/4885MAPK1 1556/4885 |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | CYP3A4 3983/4885USP2 1461/4885MAPK1 1556/4885 |
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | CYP3A4 3983/4885USP2 1461/4885MAPK1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.